А. А. Феденко
A5052911447- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Vascular Tumors and Angiosarcomas
- Gastrointestinal Tumor Research and Treatment
- Bone Tumor Diagnosis and Treatments
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Cardiac tumors and thrombi
- Lung Cancer Treatments and Mutations
- Metastasis and carcinoma case studies
- Glioma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- CNS Lymphoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Oral and Maxillofacial Pathology
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
P.A. Hertzen Moscow Oncology Research Institute
2018-2025
Ministry of Health of the Russian Federation
2016-2025
Medical Radiological Research Center
2020-2023
Ministry of Health
2019-2023
Italian Society of Periodontology and Implantology
2021-2022
USC Norris Comprehensive Cancer Center
2022
Russian Cancer Research Center NN Blokhin
2007-2021
Albert Einstein College of Medicine
2019
Creative Commons
2019
National Medical Research Center for Hematology
2019
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year [1.Nilsson B. Bümming P. Meis-Kindblom J.M. et al.Gastrointestinal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era–a population-based study western Sweden.Cancer. 2005; 103: 821-829Crossref PubMed Scopus (1027) Google Scholar]. This only covers clinically relevant GISTs, since, if investigated, a much higher number...
Four decades ago, specialized chemotherapy regimens turned osteosarcoma, once considered a uniformly fatal disease, into disease in which majority of patients survive. Though significant survival gains were made from the 1960s to 1980s, further outcome improvements appear have plateaued. This study aims comprehensively review all significant, published data regarding osteosarcoma and modern medical era order gauge treatment progress. Our results indicate that improved dramatically 1980s then...
Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In phase study, an benefit in this population was observed the addition olaratumab to doxorubicin over alone.To determine efficacy plus patients advanced/metastatic STS.ANNOUNCE confirmatory, 3, double-blind, randomized trial conducted at 110 sites 25 countries from September 2015 December 2018; final date follow-up 5, 2018. Eligible were anthracycline-naive adults unresectable locally or...
<h3>Importance</h3> Standard therapy for advanced soft-tissue sarcoma has not changed substantially in decades, and patient prognosis remains poor. Aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed clinical activity against phase 1 studies. <h3>Objective</h3> To evaluate efficacy safety aldoxorubicin vs doxorubicin patients with sarcoma. <h3>Design, Setting, Participants</h3> International, multicenter, 2b, open-label, randomized study at general community practices,...
This study explored the combination of FAP-IL2v, a novel immune-cytokine, with pembrolizumab in patients advanced and/or metastatic melanoma. open-label, multicenter, phase 1b clinical (NCT03875079) evaluated safety, tolerability, pharmacodynamics, pharmacokinetics (PK), and antitumor activity FAP-IL2v (simlukafusp alfa, RO6874281) pembrolizumab. Patients melanoma were either checkpoint inhibitor (CPI)-naïve or -experienced. received 10 mg continuously once every three weeks (Q3W) an...
Abstract Background Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib trabectedin are licensed for treatment from second-line, but very little contradictory data available on their activity ASPS. Lacking ongoing and/or planned clinical trials, we conducted a multi-institutional study involving reference sites Europe, U.S., Japan, within World Sarcoma Network, to investigate efficacy of pazopanib...
<h3>Importance</h3> Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well the potential to respond new targeted drugs. Little known on activity of anthracycline-based regimens, gemcitabine-based pazopanib in this disease. <h3>Objective</h3> To report patients advanced ES. <h3>Design, Setting, Participants</h3> Seventeen reference centers Europe, United States, Japan contributed data retrospective analysis...
To evaluate an immunohistochemical panel differentiating endometrial stromal sarcoma (ESS) from uterine leiomyosarcoma (ULMS) and leiomyoma (LM).94 cases (28 ESS, 41 ULMS, 25 LM) were retrieved arrayed. 10 immunomarkers (estrogen receptor (ER), progesterone (PR), CD10, smooth muscle actin, desmin, h-caldesmon, transgelin, GEM, ASC1, stathmin1) used. A predictive model was constructed examined by receiver operating characteristics curve analysis to determine area under the (AUC).The...
Background Intimal sarcoma (InS) is an exceedingly rare neoplasm with unfavorable prognosis, for which new potentially active treatments are under development. We report on the activity of anthracycline‐based regimens, gemcitabine‐based and pazopanib in patients InS. Methods Seventeen reference centers Europe, United States, Japan contributed data to this retrospective analysis. Patients MDM2‐positive InS who were treated or between October 2001 January 2018 selected. Local pathological...
Background. Combination of 5-HT3-receptor inhibitors and NK1-inhibitors with dexamethasone olanzapine is the standard-of-care measure for prevention chemotherapy-induced nausea vomiting in autologous hematopoietic stem cell transplant (auto-HCT) recipients. Aim. To assess efficacy toxicity netupitant/palonosetron (NEPA) as monotherapy induced by pretransplant conditioning. Materials methods. This prospective study included patients (n = 21) who underwent auto-HCT at P.A. Herzen Moscow...
Angiosarcoma is a rare malignant neoplasm that develops from endothelial cells and can affect any tissue organ, but most commonly the skin of head neck. This tumor characterized by aggressive progression early hematogenous metastasis, which leads to an unfavorable prognosis underscores importance diagnosing this pathology at its stages. Early detection angiosarcomas quite challenging due complexity differential diagnosis establishing pathomorphological diagnosis. The article presents...
<div>AbstractPurpose:<p>This study explored the combination of fibroblast activation protein (FAP) IL2 variant (FAP-IL2v), a novel immune-cytokine, with pembrolizumab in patients advanced and/or metastatic melanoma.</p>Patients and Methods:<p>This open-label, multicenter, phase Ib clinical (NCT03875079) evaluated safety, tolerability, pharmacodynamics, pharmacokinetics, antitumor activity FAP-IL2v (simlukafusp alfa, RO6874281) pembrolizumab. Patients melanoma were...
<p>Supplementary methods</p>
<p>Characterization of patients with complete or partial response</p>
<p>Overview of AEs</p>
<p>Representativeness of study participants</p>
<p>Baseline patient characteristics</p>